Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose

<i>”Hemophilia B is a rare genetic disorder that prevents normal blood clotting for people who can’t generate the factor IX (FIX) protein. According to the World Federation of Hemophilia, 38,000 people have the disorder.”</i>